{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:44:53Z","timestamp":1789469093018,"version":"build-2803163510"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Camelid variable heavy-chain (VHH) nanobodies have emerged as a promising class of single-domain antibodies with significant potential for combating bacterial and parasitic infections. Their small molecular size, high solubility, exceptional physicochemical stability, and ability to recognize cryptic or conformational epitopes inaccessible to conventional antibodies enable unique therapeutic applications. This review summarizes recent advances in the biology, mechanisms of action, engineering, and translational potential of camelid VHH nanobodies against bacterial and parasitic pathogens. In bacterial infections, nanobodies primarily function as anti-virulence agents by neutralizing toxins, inhibiting bacterial adhesion and invasion, disrupting secretion systems, preventing biofilm formation, and targeting antimicrobial resistance determinants such as \u03b2-lactamases. In protozoal diseases, they exhibit diverse mechanisms including direct killing, inhibition of host-cell invasion, disruption of surface protein trafficking, interference with metabolic pathways, and blockade of transmission stages. We further discuss current approaches for nanobody generation, recombinant production, molecular engineering, and optimization, together with challenges related to pharmacokinetics, immunogenicity, manufacturing, and clinical translation. Finally, emerging applications involving artificial intelligence-assisted nanobody design, nanotechnology-based delivery systems, One Health strategies, and outbreak preparedness are highlighted. Collectively, camelid VHH nanobodies represent a versatile and highly engineerable platform with considerable potential to address antimicrobial resistance, and accelerate the development of next-generation antimicrobial therapeutics.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1943866","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:33:51Z","timestamp":1789464831000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanisms and applications of camelid variable heavy-chain nanobodies against bacterial and parasitic protozoal pathogens"],"prefix":"10.3389","volume":"17","author":[{"given":"Hattan S.","family":"Gattan","sequence":"first","affiliation":[{"name":"Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University","place":["Jeddah, Saudi Arabia"]},{"name":"Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thamir A.","family":"Alandijany","sequence":"additional","affiliation":[{"name":"Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University","place":["Jeddah, Saudi Arabia"]},{"name":"Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13385","article-title":"Nanobody-based heavy chain antibodies and chimeric antibodies","volume":"328","author":"Koch-Nolte","year":"2024","journal-title":"Immunol Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.slasd.2025.100251","article-title":"Nanobodies: a new frontier in antiviral therapies","volume":"35","author":"Mohammed","year":"2025","journal-title":"SLAS Discov Advancing Life Sci R D"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2024.1389548","article-title":"Next generation single-domain antibodies against respiratory zoonotic RNA viruses","volume":"11","author":"Swart","year":"2024","journal-title":"Front Mol Biosci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cimid.2018.09.009","article-title":"Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases","volume":"60","author":"Lafaye","year":"2018","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/pro.5176","article-title":"On the humanization of VHHs: prospective case studies, experimental and computational characterization of structural determinants for functionality","volume":"33","author":"Fern\u00e1ndez-Quintero","year":"2024","journal-title":"Protein Sci A Publ Protein Soc"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1647230","article-title":"Comparative analysis of CDR3 length-dependent patterns in VHHs","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/pro.4450","article-title":"Molecular basis for thermal stability and affinity in a VHH: contribution of the framework region and its influence in the conformation of the CDR3","volume":"31","author":"Kinoshita","year":"2022","journal-title":"Protein Sci A Publ Protein Soc"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/pro.70189","article-title":"Improving the solubility of single domain antibodies using VH-like hallmark residues","volume":"34","author":"Uto","year":"2025","journal-title":"Protein Sci A Publ Protein Soc"},{"key":"B10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/antib11010010","article-title":"Construction of a humanized artificial VHH library reproducing structural features of camelid VHHs for therapeutics","volume":"11","author":"Murakami","year":"2022","journal-title":"Antibodies (Basel Switzerland)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/s0167-4838(99)00030-8","article-title":"Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies","volume":"1431","author":"van der Linden","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00865","article-title":"Enhancing stability of camelid and shark single domain antibodies: an overview","volume":"8","author":"Goldman","year":"2017","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1021\/bi011239a","article-title":"Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains","volume":"41","author":"Ewert","year":"2002","journal-title":"Biochemistry"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2020.105607","article-title":"Nanobody production can be simplified by direct secretion from Escherichia coli","volume":"170","author":"Iwaki","year":"2020","journal-title":"Protein Expression Purif"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24162860","article-title":"High expression achievement of active and robust anti-\u03b22 microglobulin nanobodies via E.coli hosts selection","volume":"24","author":"Li","year":"2019","journal-title":"Mol (Basel Switzerland)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzv032","article-title":"An efficient protocol towards site-specifically clickable nanobodies in high yield: cytoplasmic expression in Escherichia coli combined with intein-mediated protein ligation","volume":"28","author":"Ta","year":"2015","journal-title":"Protein Eng Design Select PEDS"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.5812\/tms.114888","article-title":"The potential applicability of single-domain antibodies (VHH): from checkpoint blockade to infectious disease therapy","volume":"1","author":"Kozani","year":"2021","journal-title":"Trends Med Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.01.008","article-title":"Rapid delivery of nanobodies\/V(H)Hs into living cells via expressing in vitro-transcribed mRNA","volume":"17","author":"Zhou","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-12-801076-1.00010-1","article-title":"Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: application to brain imaging","volume":"26","author":"Li","year":"2012","journal-title":"FASEB J Off Publ Fed Am Societies For Exp Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/b978-1-4160-4044-6.50124-2","article-title":"Discovery and characterization of cross-reactive single-domain antibodies targeting key virulence factors of Salmonella and Shigella","volume":"210","author":"Ochoa","year":"2023","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12668-025-02304-8","article-title":"A rapid nanobody based approach for developing antimicrobials against drug-resistant bacteria and yeasts","volume":"16","author":"Banerjee","year":"2025","journal-title":"BioNanoScience"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122187","article-title":"Inhibition of type VI secretion by an anti-TssM llama nanobody","volume":"10","author":"Nguyen","year":"2015","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29071431","article-title":"Camel-derived nanobodies as potent inhibitors of New Delhi metallo-\u03b2-lactamase-1 enzyme","volume":"29","author":"Ben Abderrazek","year":"2024","journal-title":"Mol (Basel Switzerland)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.104927","article-title":"Targeting hemoglobin receptors IsdH and IsdB of Staphylococcus aureus with a single VHH antibody inhibits bacterial growth","volume":"299","author":"Valenciano-Bellido","year":"2023","journal-title":"J Biol Chem"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002072","article-title":"High affinity nanobodies against the Trypanosome brucei VSG are potent trypanolytic agents that block endocytosis","volume":"7","author":"Stijlemans","year":"2011","journal-title":"PloS Pathog"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001902","article-title":"Affinity is an important determinant of the anti-trypanosome activity of nanobodies","volume":"6","author":"Caljon","year":"2012","journal-title":"PloS Negl Trop Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/pim.12718","article-title":"Camel nanobodies: promising molecular tools against leishmaniasis","volume":"42","author":"Abu Alshamat","year":"2020","journal-title":"Parasite Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008031","article-title":"A nanobody targeting the translocated intimin receptor inhibits the attachment of enterohemorrhagic E. coli to human colonic mucosa","volume":"15","author":"Ruano-Gallego","year":"2019","journal-title":"PloS Pathog"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/trstmh\/trt114","article-title":"Immunoreaction of a recombinant nanobody from camelid single domain antibody fragment with Acinetobacter baumannii","volume":"108","author":"Payandeh","year":"2014","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/ani15213207","article-title":"Protective effect of nanobodies targeting Sip protein against Streptococcus agalactiae infection in Tilapia (Oreochromis niloticus)","volume":"15","author":"Wang","year":"2025","journal-title":"Anim Open Access J MDPI"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.ra118.003888","article-title":"Structural basis of V(H)H-mediated neutralization of the food-borne pathogen Listeria monocytogenes","volume":"293","author":"King","year":"2018","journal-title":"J Biol Chem"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-012-4518-x","article-title":"Isolation and characterization of protective anti-LPS nanobody against V. cholerae O1 recognizing Inaba and Ogawa serotypes","volume":"97","author":"Ebrahimizadeh","year":"2013","journal-title":"Appl Microbiol Biotechnol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2023.106411","article-title":"Development of a bispecific nanobody anti-F17 fimbria as a potential therapeutic tool","volume":"215","author":"Dhehibi","year":"2024","journal-title":"Protein Expression Purif"},{"key":"B34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.vetimm.2011.04.004","article-title":"Evaluation of a nanobody phage display library constructed from a Brucella-immunised camel","volume":"142","author":"Abbady","year":"2011","journal-title":"Vet Immunol Immunopathol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/9781444397741.ch5","article-title":"Phenotypic knockouts of selected metabolic pathways by targeting enzymes with camel-derived nanobodies (V(HH)s)","volume":"30","author":"Jim\u00e9nez","year":"2015","journal-title":"Metab Eng"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.31.1_supplement.912.11","article-title":"Nanobody mediated neutralization of Listeria monocytogenes","volume":"31","author":"Brooks","year":"2018","journal-title":"FASEB J"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/2211-5463.70166","article-title":"Engineering tandem VHHs to target different epitopes to enhance antibody-dependent cell-mediated cytotoxicity","volume":"16","author":"Xu","year":"2025","journal-title":"FEBS Open Bio"},{"key":"B38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/00063030-200923020-00003","article-title":"Strategies to extend plasma half-lives of recombinant antibodies","volume":"23","author":"Kontermann","year":"2009","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000412","article-title":"Neglected tropical diseases in Sub-Saharan Africa: review of their prevalence, distribution, and disease burden","volume":"3","author":"Hotez","year":"2009","journal-title":"PloS Negl Trop Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.7554\/elife.100066.2","article-title":"Allosteric inhibition of trypanosomatid pyruvate kinases by a camelid single-domain antibody","volume":"13","author":"Pinto Torres","year":"2025","journal-title":"eLife"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1013884","article-title":"Pfs48\/45 nanobodies block Plasmodium falciparum transmission","volume":"22","author":"Lyons","year":"2026","journal-title":"PloS Pathog"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-010-0387-6","article-title":"A recombinant dromedary antibody fragment (VHH or nanobody) directed against human Duffy antigen receptor for chemokines","volume":"67","author":"Smolarek","year":"2010","journal-title":"Cell Mol Life Sci CMLS"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109923","article-title":"Nanobody-mediated macromolecular crowding induces membrane fission and remodeling in the African trypanosome","volume":"37","author":"Hempelmann","year":"2021","journal-title":"Cell Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m307341200","article-title":"Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm","volume":"279","author":"Stijlemans","year":"2004","journal-title":"J Biol Chem"},{"key":"B45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The therapeutic potential of nanobodies","volume":"34","author":"Jov\u010devska","year":"2020","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu Rev Biochem"},{"key":"B47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/antib8010012","article-title":"Targeted nanobody-based molecular tracers for nuclear imaging and image-guided surgery","volume":"8","author":"Debie","year":"2019","journal-title":"Antibodies (Basel Switzerland)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01603","article-title":"Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics","volume":"8","author":"Bannas","year":"2017","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m806889200","article-title":"General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold","volume":"284","author":"Vincke","year":"2009","journal-title":"J Biol Chem"},{"key":"B50","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/imr.13381","article-title":"Single domain antibody: development and application in biotechnology and biopharma","volume":"328","author":"Yu","year":"2024","journal-title":"Immunol Rev"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1042\/bst20241419","article-title":"Advances in nanobody multimerization and multispecificity: from in vivo assembly to in vitro production","volume":"53","author":"Al-Seragi","year":"2025","journal-title":"Biochem Soc Trans"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antib8010001","article-title":"Single-domain antibodies and their formatting to combat viral infections","volume":"8","author":"De Vlieger","year":"2018","journal-title":"Antibodies (Basel Switzerland)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.1c08092","article-title":"Self-assembled nanobodies as selectively targeted, nanostructured, and multivalent materials","volume":"13","author":"S\u00e1nchez-Garc\u00eda","year":"2021","journal-title":"ACS Appl Materials Interfaces"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-019-00104-w","article-title":"Nanobody approval gives domain antibodies a boost","volume":"18","author":"Morrison","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2249814","article-title":"Current status and future expectations of nanobodies in oncology trials","volume":"32","author":"De Pauw","year":"2023","journal-title":"Expert Opin Invest Drugs"},{"key":"B56","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41467-021-27610-z","article-title":"A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo","volume":"13","author":"Hanke","year":"2022","journal-title":"Nat Commun"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1128\/cvi.05075-11","article-title":"Cross-protection of chicken immunoglobulin Y antibodies against H5N1 and H1N1 viruses passively administered in mice","volume":"18","author":"Wallach","year":"2011","journal-title":"Clin Vaccine Immunol CVI"},{"key":"B58","doi-asserted-by":"publisher","first-page":"109869","DOI":"10.2139\/ssrn.3832975","article-title":"A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration","volume":"37","author":"Wu","year":"2021","journal-title":"Cell Rep"},{"key":"B59","article-title":"Preparation and property study of the recombinant Camel anti-SpaA-N single domain antibodies","volume":"28","author":"Lu","year":"2012","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi = Chin J Cell Mol Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02665","article-title":"A novel single domain antibody targeting FliC flagellin of Salmonella enterica for effective inhibition of host cell invasion","volume":"10","author":"Huen","year":"2019","journal-title":"Front Microbiol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s12010-014-0750-4","article-title":"Functional mutations in and characterization of VHH against Helicobacter pylori urease","volume":"172","author":"Hoseinpoor","year":"2014","journal-title":"Appl Biochem Biotechnol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1128\/aac.45.10.2807-2812.2001","article-title":"Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae","volume":"45","author":"Conrath","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"B63","doi-asserted-by":"publisher","first-page":"111763","DOI":"10.2139\/ssrn.6726779","article-title":"Structural basis for the inhibition of Trypanosoma brucei enolase by a camelid single-domain antibody","volume":"267","author":"Li","year":"2026","journal-title":"Mol Biochem Parasitol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ady4877","article-title":"Single\u2013amino acid variants in target epitopes can confer resistance to antibody-based therapies","volume":"17","author":"Marone","year":"2025","journal-title":"Sci Transl Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-018-0028-6","article-title":"Yeast surface display platform for rapid discovery of conformationally selective nanobodies","volume":"25","author":"McMahon","year":"2018","journal-title":"Nat Struct Mol Biol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.632687","article-title":"Immunogenicity risk profile of nanobodies","volume":"12","author":"Ackaert","year":"2021","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1039\/d1cb00023c","article-title":"Nanobodies as in vivo, non-invasive, imaging agents","volume":"2","author":"Harmand","year":"2021","journal-title":"RSC Chem Biol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2025.130884","article-title":"Nanobody-based imaging: advancing precision in molecular diagnostics","volume":"1870","author":"Eftekhari","year":"2026","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"B69","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3390\/biology14050547","article-title":"Nanobodies: from discovery to AI-driven design","volume":"14","author":"Zhu","year":"2025","journal-title":"Biology"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-animal-021419-083831","article-title":"Applications of nanobodies","volume":"9","author":"Muyldermans","year":"2021","journal-title":"Annu Rev Anim Biosci"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00653","article-title":"Camelid single-domain antibodies as an alternative to overcome challenges related to the prevention, detection, and control of neglected tropical diseases","volume":"8","author":"Fernandes","year":"2017","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01197-22","article-title":"Identification and characterization of nanobodies from a phage display library and their application in an immunoassay for the sensitive detection of African swine fever virus","volume":"61","author":"Zhao","year":"2023","journal-title":"J Clin Microbiol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-021-00533-7","article-title":"Camelid single-domain antibodies for the development of potent diagnosis platforms","volume":"25","author":"Brilhante-da-Silva","year":"2021","journal-title":"Mol Diagnosis Ther"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/ceur.202400106","article-title":"Label-free photonic biosensors: key technologies for precision diagnostics","volume":"3","author":"Soler","year":"2025","journal-title":"ChemistryEurope"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-021-00750-5","article-title":"Nanobody: a promising toolkit for molecular imaging and disease therapy","volume":"11","author":"Bao","year":"2021","journal-title":"EJNMMI Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1723343","article-title":"Unique antibodies across the animal kingdom (birds, camelids, and sharks): therapeutic potential against human respiratory viral infections","volume":"16","author":"Basabrain","year":"2025","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.4324\/9781032644257-83","article-title":"mRNA-encoded antibodies as a next-generation therapeutic paradigm: a rapid and adaptive platform for the prevention and treatment of emerging and re-emerging infectious diseases \u2014 a critical review","volume":"74","author":"Singh","year":"2026","journal-title":"Immunol Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1943866\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:33:52Z","timestamp":1789464832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1943866\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":77,"alternative-id":["10.3389\/fimmu.2026.1943866"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1943866","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"1943866"}}